CVKD Cadrenal Therapeutics, Inc. Common Stock
USHealthcareAs of 2026-10-08
Why CVKD matters now
Cadrenal Therapeutics, Inc. Common Stock (CVKD) is a US stock in Healthcare. The latest InvestLog snapshot shows $0.93 with -4.39% on the session and $3.3M in market capitalization; recent performance reads 1-month -29.58% and YTD -48.38%.
The latest financial table shown here is Q1 2026, with revenue of $0.00, net income of $-2.5M, and EPS of $-1.04. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -109.1%.
The latest indexable market news headline is "Cadrenal Therapeutics to Participate in the Lytham Partners Fall 2026 Investor Conference" from GlobeNewsWire.
Additional event context on this page matters because analyst consensus is Buy with a median target of $32.00; recent insider activity includes Pham Quang X filing S-Sale. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
4.69
P/S
0.00
EV/EBITDA
-0.65
DCF Value
$1.72
FCF Yield
-109.1%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-411.0%
ROA
-415.4%
ROIC
-670.4%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $0.00 | $-2.5M | $-1.04 |
| Q4 2025 | $0.00 | $-3.0M | $-1.41 |
| FY 2025 | $0.00 | $-13.2M | $-6.64 |
| Q3 2025 | $0.00 | $-2.7M | $-1.31 |
Analyst Ratings
Consensus
Buy
Target (Consensus)
$32.00
Target (Median)
$32.00
Target Range
$32.00 - $32.00
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Biotechnology
Country
US
Exchange
—
Beta
1.61
Cadrenal Therapeutics, Inc. operates as a biopharmaceutical enterprise primarily engaged in clinical development. The company's core focus is the advancement of Tecarfarin, a novel therapeutic agent that has received orphan drug designation. This treatment is engineered to prevent systemic thromboembolism originating from cardiac issues in patients suffering from both end-stage renal disease and atrial fibrillation. Established in 2022, the firm is headquartered in Ponte Vedra, Florida.